Literature DB >> 33058300

Deficiency of Histone Methyltransferase SET Domain-Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC.

Xue-Jing Li1, Qing-Lan Li1, Lin-Gao Ju2, Chen Zhao1, Lan-Shen Zhao1, Jia-Wen Du1, Yan Wang1, Ling Zheng1, Bao-Liang Song1, Lian-Yun Li1, Li Li3,4, Min Wu1.   

Abstract

BACKGROUND AND AIMS: Trimethylation of Lys36 on histone 3 (H3K36me3) catalyzed by histone methyltransferase SET domain-containing 2 (SETD2) is one of the most conserved epigenetic marks from yeast to mammals. SETD2 is frequently mutated in multiple cancers and acts as a tumor suppressor. APPROACH AND
RESULTS: Here, using a liver-specific Setd2 depletion model, we found that Setd2 deficiency is sufficient to trigger spontaneous HCC. Meanwhile, Setd2 depletion significantly increased tumor and tumor size of a diethylnitrosamine-induced HCC model. The mechanistic study showed that Setd2 suppresses HCC not only through modulating DNA damage response, but also by regulating lipid metabolism in the liver. Setd2 deficiency down-regulated H3K36me3 enrichment and expression of cholesterol efflux genes and caused lipid accumulation. High-fat diet enhanced lipid accumulation and promoted the development of HCC in Setd2-deficient mice. Chromatin immunoprecipitation sequencing analysis further revealed that Setd2 depletion induced c-Jun/activator protein 1 (AP-1) activation in the liver, which was trigged by accumulated lipid. c-Jun acts as an oncogene in HCC and functions through inhibiting p53 in Setd2-deficient cells.
CONCLUSIONS: We revealed the roles of Setd2 in HCC and the underlying mechanisms in regulating cholesterol homeostasis and c-Jun/AP-1 signaling.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33058300     DOI: 10.1002/hep.31594

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

2.  Methyltransferase SETD2 mediates hepatoprotection of berberine against steatosis.

Authors:  Li Dai; Shuang Lu; Tianbai Shen; Ying Li; Jianjie Chen
Journal:  Ann Transl Med       Date:  2022-05

3.  CTB-193M12.5 Promotes Hepatocellular Carcinoma Progression via Enhancing NSD1-Mediated WNT10B/Wnt/β-Catenin Signaling Activation.

Authors:  Shuhua Zhang; Mi Jiang; Huan Cao; Jun Xiong; Jianqun Xu
Journal:  J Hepatocell Carcinoma       Date:  2022-06-07

4.  SMYD5 catalyzes histone H3 lysine 36 trimethylation at promoters.

Authors:  Yanjun Zhang; Yuan Fang; Yin Tang; Shixun Han; Junqi Jia; Xinyi Wan; Jiaqi Chen; Ying Yuan; Bin Zhao; Dong Fang
Journal:  Nat Commun       Date:  2022-06-09       Impact factor: 17.694

Review 5.  H3K36 trimethylation-mediated biological functions in cancer.

Authors:  Chu Xiao; Tao Fan; He Tian; Yujia Zheng; Zheng Zhou; Shuofeng Li; Chunxiang Li; Jie He
Journal:  Clin Epigenetics       Date:  2021-10-29       Impact factor: 6.551

6.  A Ctnnb1 enhancer regulates neocortical neurogenesis by controlling the abundance of intermediate progenitors.

Authors:  Junbao Wang; Andi Wang; Kuan Tian; Xiaojiao Hua; Bo Zhang; Yue Zheng; Xiangfei Kong; Wei Li; Lichao Xu; Juan Wang; Zhiqiang Li; Ying Liu; Yan Zhou
Journal:  Cell Discov       Date:  2022-08-02       Impact factor: 38.079

7.  A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses.

Authors:  Guangzhen Cai; Jinghan Zhu; Deng Ning; Ganxun Li; Yuxin Zhang; Yixiao Xiong; Junnan Liang; Chengpeng Yu; Xiaoping Chen; Huifang Liang; Zeyang Ding
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786

8.  SETD3 Methyltransferase Regulates PLK1 Expression to Promote In Situ Hepatic Carcinogenesis.

Authors:  Meng Cheng; Qingmiao Yang; Yafei Liu; Meng-Jie Zhao; Xinyuan Du; Jiaqi Sun; Wen-Jie Shu; Zan Huang; Jianping Bi; Ximing Xu; Hai-Ning Du
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.